Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Treatment Options in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders

Author(s): Paulus Rommer* and Uwe K. Zettl

Volume 28, Issue 6, 2022

Published on: 30 November, 2021

Page: [428 - 436] Pages: 9

DOI: 10.2174/1381612827666210920151231

Price: $65

conference banner
Abstract

There are few diseases where as much therapeutic progress has been made in recent years as in multiple sclerosis. Nine different drug classes with more than a dozen approved therapies are now available. Similarly, there have been unimaginable advances in understanding neuromyelitis optica (now neuromyelitis optica spectrum disorder [NMOSD]) over the past 15 years. Building on the knowledge gained, the first therapies have been approved in recent years. In this review, we aim to present all therapies approved for the treatment of MS or NMOSD. The different forms of application, different approval criteria and most important side effects will be presented. This work is intended for physicians who are interested in MS and NMOSD therapies and want to get a first overview and does not replace the respective guidelines of the regulatory authorities.

Keywords: Multiple sclerosis, NMOSD, treatment, monoclonal antiboides, side effects, immune-modulation.

« Previous Next »
[1]
Lassmann H. Multiple sclerosis pathology. Cold Spring Harb Perspect Med 2018; 8(3): a028936.
[http://dx.doi.org/10.1101/cshperspect.a028936] [PMID: 29358320]
[2]
Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med 2018; 378(2): 169-80.
[http://dx.doi.org/10.1056/NEJMra1401483] [PMID: 29320652]
[3]
Zettl UK, Stüve O, Patejdl R. Immune-mediated CNS diseases: a review on nosological classification and clinical features. Autoimmun Rev 2012; 11(3): 167-73.
[http://dx.doi.org/10.1016/j.autrev.2011.05.008] [PMID: 21619943]
[4]
Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17(2): 162-73.
[http://dx.doi.org/10.1016/S1474-4422(17)30470-2] [PMID: 29275977]
[5]
Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008; 14(9): 1157-74.
[http://dx.doi.org/10.1177/1352458508096878] [PMID: 18805839]
[6]
Rommer PS, Milo R, Han MH, et al. Immunological aspects of approved MS therapeutics. Front Immunol 2019; 10: 1564.
[http://dx.doi.org/10.3389/fimmu.2019.01564] [PMID: 31354720]
[7]
Rommer PS, Berger K, Ellenberger D, et al. Management of MS patients treated with daclizumab - a case series of 267 patients. Front Neurol 2020; 11: 996.
[http://dx.doi.org/10.3389/fneur.2020.00996] [PMID: 33013658]
[8]
Rommer PS, Zettl UK. Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients. Expert Opin Pharmacother 2018; 19(5): 483-98.
[http://dx.doi.org/10.1080/14656566.2018.1446944] [PMID: 29528247]
[9]
Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364(9451): 2106-12.
[http://dx.doi.org/10.1016/S0140-6736(04)17551-X] [PMID: 15589308]
[10]
Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B. Neuromyelitis optica. Nat Rev Dis Primers 2020; 6(1): 85.
[http://dx.doi.org/10.1038/s41572-020-0214-9] [PMID: 33093467]
[11]
Wang Y, Chang H, Zhang X, Yin L. Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis. Mult Scler Relat Disord 2021; 50: 102843.
[http://dx.doi.org/10.1016/j.msard.2021.102843] [PMID: 33609924]
[12]
Collongues N, Ayme-Dietrich E, Monassier L, de Seze J. Pharmacotherapy for neuromyelitis optica spectrum disorders: current management and future options. Drugs 2019; 79(2): 125-42.
[http://dx.doi.org/10.1007/s40265-018-1039-7] [PMID: 30623348]
[13]
Sellner J, Sitte HH, Rommer PS. Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: Implications from immunology, the FcRn pathway and clinical experience. Drug Discov Today 2021; S1359-6446(21): 00154-9.
[14]
Solomon AJ, Klein EP, Bourdette D. “Undiagnosing” multiple sclerosis: the challenge of misdiagnosis in MS. Neurology 2012; 78(24): 1986-91.
[http://dx.doi.org/10.1212/WNL.0b013e318259e1b2] [PMID: 22581930]
[15]
Solomon AJ, Bourdette DN, Cross AH, et al. The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study. Neurology 2016; 87(13): 1393-9.
[http://dx.doi.org/10.1212/WNL.0000000000003152] [PMID: 27581217]
[16]
Rommer PS, Zettl UK. Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. Lancet Neurol 2018; 17(6): 497-8.
[http://dx.doi.org/10.1016/S1474-4422(18)30161-3] [PMID: 29778357]
[17]
Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353(4): 369-74.
[http://dx.doi.org/10.1056/NEJMoa051782] [PMID: 15947079]
[18]
Ellenberger D, Flachenecker P, Haas J, et al. Is benign MS really benign? What a meaningful classification beyond the EDSS must take into consideration. Mult Scler Relat Disord 2020; 46: 102485.
[http://dx.doi.org/10.1016/j.msard.2020.102485] [PMID: 32980646]
[19]
Ellenberger D, Flachenecker P, Fneish F, et al. Aggressive multiple sclerosis: a matter of measurement and timing. Brain 2020; 143(11): e97.
[http://dx.doi.org/10.1093/brain/awaa306] [PMID: 33175163]
[20]
Hauser SL, Josephson SA, Johnston SC. Multiple sclerosis: monotherapy rules. Ann Neurol 2013; 73(3): A5-6.
[http://dx.doi.org/10.1002/ana.23886] [PMID: 23596013]
[21]
Lünemann JD, Ruck T, Muraro PA, Bar-Or A, Wiendl H. Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Nat Rev Neurol 2020; 16(1): 56-62.
[http://dx.doi.org/10.1038/s41582-019-0268-z] [PMID: 31649335]
[22]
Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs. early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol 2019; 76(5): 536-41.
[http://dx.doi.org/10.1001/jamaneurol.2018.4905] [PMID: 30776055]
[23]
Bsteh G, Feige J, Ehling R, et al. Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors. Mult Scler 2017; 23(9): 1241-8.
[http://dx.doi.org/10.1177/1352458516675751] [PMID: 27765877]
[24]
Zettl UK, Henze T, Essner U, Flachenecker P. Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I). Eur J Health Econ 2014; 15(9): 953-66.
[http://dx.doi.org/10.1007/s10198-013-0537-5] [PMID: 24292503]
[25]
Rommer PS, Eichstädt K, Ellenberger D, et al. Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry. Mult Scler 2019; 25(12): 1641-52.
[http://dx.doi.org/10.1177/1352458518799580] [PMID: 30230952]
[26]
rebif-epar-product-information_en.pdf [cited 2021 Jan 22]. Available from: https://www.ema.europa.eu/en/documents/product-information/rebif-epar-product-information_en.pdf
[27]
103780s5178s5179lbl.pdf [cited 2021 Jan 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103780s5178s5179lbl.pdf
[28]
avonex-epar-product-information_en.pdf [cited 2021 Jan 22]. Available from: https://www.ema.europa.eu/en/documents/product-information/avonex-epar-product-information_en.pdf
[29]
103628s5189lbl.pdf [cited 2021 Jan 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103628s5189lbl.pdf
[30]
betaferon-epar-product-information_en.pdf [cited 2021 Jan 22]. Available from: https://www.ema.europa.eu/en/documents/product-information/betaferon-epar-product-information_en.pdf
[31]
103471s5157lbl.pdf [cited 2021 Jan 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/103471s5157lbl.pdf
[32]
plegridy-epar-product-information_en.pdf [cited 2021 Jan 22]. Available from: https://www.ema.europa.eu/en/documents/product-information/plegridy-epar-product-information_en.pdf
[33]
PLEGRIDY (peginterferon beta-1a) injection. 24
[34]
Rebif, Interferon beta-1a. 1995; 3
[35]
020622s102lbl.pdf [cited 2021 Jan 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020622s102lbl.pdf
[36]
Drugs@FDA: FDA-Approved Drugs [cited 2021 Jan 20]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206921
[37]
201711_en.pdf [cited 2021 Jan 20]. Available from: https://www.ema.europa.eu/en/documents/psusa/glatiramer-list-nationally-authorised-medicinal-products-psusa/00001529/201711_en.pdf
[38]
Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45(7): 1268-76.
[http://dx.doi.org/10.1212/WNL.45.7.1268] [PMID: 7617181]
[39]
Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998; 50(3): 701-8.
[http://dx.doi.org/10.1212/WNL.50.3.701] [PMID: 9521260]
[40]
DE_H_5283_004_FinalPI_2of2.pdf [cited 2021 Jan 20]. Available from: https://mri.cts-mrp.eu/Human/Downloads/DE_H_5283_004_FinalPI_2of2.pdf
[41]
aubagio-epar-product-information_en.pdf [cited 2021 Jan 23]. Available from: https://www.ema.europa.eu/en/documents/product-information/aubagio-epar-product-information_en.pdf
[42]
202992s003lbl.pdf [cited 2021 Jan 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202992s003lbl.pdf
[43]
O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365(14): 1293-303.
[http://dx.doi.org/10.1056/NEJMoa1014656] [PMID: 21991951]
[44]
Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13(3): 247-56.
[http://dx.doi.org/10.1016/S1474-4422(13)70308-9] [PMID: 24461574]
[45]
tecfidera-epar-product-information_en.pdf [cited 2021 Jan 23]. Available from: https://www.ema.europa.eu/en/documents/product-information/tecfidera-epar-product-information_en.pdf
[46]
204063lbl.pdf [cited 2021 Jan 23]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204063lbl.pdf
[47]
Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367(12): 1087-97.
[http://dx.doi.org/10.1056/NEJMoa1206328] [PMID: 22992072]
[48]
Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367(12): 1098-107.
[http://dx.doi.org/10.1056/NEJMoa1114287] [PMID: 22992073]
[49]
Vukusic S, Michel L, Leguy S, Lebrun-Frenay C. Pregnancy with multiple sclerosis. Rev Neurol (Paris) 2020; 177(3): 180-90.
[http://dx.doi.org/10.1016/j.neurol.2020.05.005]
[50]
Am B. Indications and usage 2 dosage and administration. 19
[51]
211855s000lbl.pdf [cited 2021 Jan 23]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211855s000lbl.pdf
[52]
351922_FAQ_Gilenya.pdf [cited 2021 Jan 12]. Available from: https://www.novartis.de/system/files/product-info/351922_FAQ_Gilenya.pdf
[53]
gilenya-epar-product-information_en.pdf [cited 2021 Jan 12]. Available from: https://www.ema.europa.eu/en/documents/product-information/gilenya-epar-product-information_en.pdf
[54]
Kappos L, Radue E-W, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362(5): 387-401.
[http://dx.doi.org/10.1056/NEJMoa0909494] [PMID: 20089952]
[55]
Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362(5): 402-15.
[http://dx.doi.org/10.1056/NEJMoa0907839] [PMID: 20089954]
[56]
Chitnis T, Arnold DL, Banwell B, et al. Trial of fingolimod versus interferon Beta-1a in pediatric multiple sclerosis. N Engl J Med 2018; 379(11): 1017-27.
[http://dx.doi.org/10.1056/NEJMoa1800149] [PMID: 30207920]
[57]
Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2016; 387(10023): 1075-84.
[http://dx.doi.org/10.1016/S0140-6736(15)01314-8] [PMID: 26827074]
[58]
Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 2018; 391(10127): 1263-73.
[http://dx.doi.org/10.1016/S0140-6736(18)30475-6] [PMID: 29576505]
[59]
mayzent-epar-product-information_en.pdf [cited 2021 Jan 12]. Available from: https://www.ema.europa.eu/en/documents/product-information/mayzent-epar-product-information_en.pdf
[60]
209884Orig1s000Approv.pdf [cited 2021 Jan 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209884Orig1s000Approv.pdf
[61]
Subei AM, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNS Drugs 2015; 29(7): 565-75.
[http://dx.doi.org/10.1007/s40263-015-0261-z] [PMID: 26239599]
[62]
FRANCISCO EM. Zeposia. European Medicines Agency. 2020. [cited 2021 Jan 12]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zeposia
[63]
209899s000lbl.pdf [cited 2021 Jan 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf
[64]
Comi G, Kappos L, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol 2019; 18(11): 1009-20.
[http://dx.doi.org/10.1016/S1474-4422(19)30239-X] [PMID: 31492651]
[65]
Cohen JA, Comi G, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol 2019; 18(11): 1021-33.
[http://dx.doi.org/10.1016/S1474-4422(19)30238-8] [PMID: 31492652]
[66]
mavenclad-epar-product-information_en.pdf [cited 2021 Jan 15]. Available from: https://www.ema.europa.eu/en/documents/product-information/mavenclad-epar-product-information_en.pdf
[67]
Commissioner O of the. FDA approves new oral treatment for multiple sclerosis. FDA. FDA 2020. [cited 2021 Jan 15]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-oral-treatment-multiple-sclerosis
[68]
Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010; 362(5): 416-26.
[http://dx.doi.org/10.1056/NEJMoa0902533] [PMID: 20089960]
[69]
questions-answers-withdrawal-marketing-authorisation-application-movectro_en.pdf [cited 2021 Jan 15]. Available from: https://www.ema.europa.eu/en/documents/other/questions-answers-withdrawal-marketing-authorisation-application-movectro_en.pdf
[70]
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis - PubMed [cited 2021 Jan 15]. Available from: https://pubmed.ncbi.nlm.nih.gov/20089960/
[71]
Giovannoni G, Soelberg Sorensen P, Cook S, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler 2018; 24(12): 1594-604.
[http://dx.doi.org/10.1177/1352458517727603] [PMID: 28870107]
[72]
Comi G, Cook S, Rammohan K, et al. Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study. Ther Adv Neurol Disord 2018; 11: 1756285617753365.
[http://dx.doi.org/10.1177/1756285617753365] [PMID: 29399054]
[73]
Leist T, Cook S, Comi G, et al. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Mult Scler Relat Disord 2020; 46: 102572.https://www.msard-journal.com/article/S2211-0348(20)30646-5/abstract [Internet].
[http://dx.doi.org/10.1016/j.msard.2020.102572] [PMID: 33296971]
[74]
Pakpoor J, Disanto G, Altmann DR, et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm 2015; 2(6): e158.
[http://dx.doi.org/10.1212/NXI.0000000000000158] [PMID: 26468472]
[75]
tysabri-epar-product-information_en.pdf [cited 2021 Jan 23]. Available from: https://www.ema.europa.eu/en/documents/product-information/tysabri-epar-product-information_en.pdf
[76]
125104s0576lbl.pdf [cited 2021 Jan 23]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125104s0576lbl.pdf
[77]
Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354(9): 899-910.
[http://dx.doi.org/10.1056/NEJMoa044397] [PMID: 16510744]
[78]
Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354(9): 911-23.
[http://dx.doi.org/10.1056/NEJMoa044396] [PMID: 16510745]
[79]
Moiola L, Rommer PS, Zettl UK. Prevention and management of adverse effects of disease modifying treatments in multiple sclerosis. Curr Opin Neurol 2020; 33(3): 286-94.
[http://dx.doi.org/10.1097/WCO.0000000000000824] [PMID: 32374570]
[80]
lemtrada-epar-product-information_en.pdf [cited 2021 Jan 23]. Available from: https://www.ema.europa.eu/en/documents/product-information/lemtrada-epar-product-information_en.pdf
[81]
103948s5158lbl.pdf [cited 2021 Jan 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103948s5158lbl.pdf
[82]
lemtrada-article-20-procedure-use-multiple-sclerosis-medicine-lemtrada-restricted-while-ema-review_en.pdf [cited 2021 Jan 23]. Available from: https://www.ema.europa.eu/en/documents/referral/lemtrada-article-20-procedure-use-multiple-sclerosis-medicine-lemtrada-restricted-while-ema-review_en.pdf
[83]
Measures to minimise risk of serious side effects of multiple sclerosis medicine Lemtrada. 1995; 3
[84]
Rommer PS, Dudesek A, Stüve O, Zettl UK. Monoclonal antibodies in treatment of multiple sclerosis. Clin Exp Immunol 2014; 175(3): 373-84.
[http://dx.doi.org/10.1111/cei.12197] [PMID: 24001305]
[85]
ocrevus-epar-product-information_en.pdf [cited 2021 Jan 23]. Available from: https://www.ema.europa.eu/en/documents/product-information/ocrevus-epar-product-information_en.pdf
[86]
Anonymous. Ocrevus. European Medicines Agency. 2018. [cited 2021 Jan 18]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus
[87]
OCREVUSTM (ocrelizumab) injection. 18
[88]
125326s070lbl.pdf [cited 2021 Jan 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125326s070lbl.pdf
[89]
Novartis announces FDA and EMA filing acceptance of ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS). Novartis [cited 2021 Jan 18]. Available from: https://www.novartis.com/news/media-releases/novartis-announces-fda-and-ema-filing-acceptance-ofatumumab-novel-b-cell-therapy-patients-relapsing-forms-multiple-sclerosis-rms
[90]
Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS) - PubMed [cited 2021 Jan 21]. Available from: https://pubmed.ncbi.nlm.nih.gov/24272588/
[91]
Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2020; 19(4): 298-306.
[http://dx.doi.org/10.1016/S1474-4422(20)30066-1] [PMID: 32199095]
[92]
Hartung H-P, Aktas O. Old and new breakthroughs in neuromyelitis optica. Lancet Neurol 2020; 19(4): 280-1.
[http://dx.doi.org/10.1016/S1474-4422(20)30062-4] [PMID: 32199085]
[93]
Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol 2021; 20(1): 60-7.
[http://dx.doi.org/10.1016/S1474-4422(20)30392-6] [PMID: 33186537]
[94]
soliris-epar-product-information_en.pdf [cited 2021 Jan 18]. Available from: https://www.ema.europa.eu/en/documents/product-information/soliris-epar-product-information_en.pdf
[95]
125166s431lbl.pdf [cited 2021 Jan 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125166s431lbl.pdf
[96]
Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 2019; 381(7): 614-25.
[http://dx.doi.org/10.1056/NEJMoa1900866] [PMID: 31050279]
[97]
Commissioner O of the. FDA approves first treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease of the central nervous system. FDA. FDA 2020. [cited 2021 Jan 18]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-neuromyelitis-optica-spectrum-disorder-rare-autoimmune-disease-central
[98]
Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology - PubMed [cited 2021 Jan 21]. Available from: https://pubmed.ncbi.nlm.nih.gov/32820020/
[99]
Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 2019; 381(22): 2114-24.
[http://dx.doi.org/10.1056/NEJMoa1901747] [PMID: 31774956]
[100]
Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 2020; 19(5): 402-12.
[http://dx.doi.org/10.1016/S1474-4422(20)30078-8] [PMID: 32333898]
[101]
761149s000lbl.pdf [cited 2021 Jan 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761149s000lbl.pdf
[102]
Roche - Roche’s marketing applications for satralizumab in neuromyelitis optica spectrum disorder accepted for review by EMA and FDA [cited 2021 Jan 18]. Available from: https://www.roche.com/media/releases/med-cor-2019-10-30.htm
[103]
Lotan I, McGowan R, Levy M. Anti-IL-6 therapies for neuromyelitis optica spectrum disorders: A systematic review of safety and efficacy. Curr Neuropharmacol 2021; 19(2): 220-32.
[http://dx.doi.org/10.2174/1570159X18666200429010825] [PMID: 32348222]
[104]
761142s000lbl.pdf [cited 2021 Jan 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761142s000lbl.pdf
[105]
Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 2019; 394(10206): 1352-63.
[http://dx.doi.org/10.1016/S0140-6736(19)31817-3] [PMID: 31495497]
[106]
Anonymous. EMEA-001911-PIP01-15-M02 [Internet]. European Medicines Agency. 2018. [cited 2021 Jan 18]. Available from: https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001911-pip01-15-m02

Rights & Permissions Print Cite
Article Metrics
118
1
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy